{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"GCTK","limit":50},"count":50,"signals":[{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":52,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results, and financial condition. Until adequate reimbursement or insurance coverage is established, patients may have to bear the financial cost of our products. To mitiga","filed_date":"2026-03-30","accession":"0001493152-26-013656","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013656.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":17,"context":"executive compensation for our last two completed fiscal years and an Outstanding Equity Awards at Fiscal Year End Table for our last completed fiscal year. These reporting obligations extend only to named executive officers. Individuals we refer to as our named executive officers include (i) all individuals serving as our Chief Executive Officer during the fiscal year ended December 31, 2025 and (ii) our two most highl","filed_date":"2026-03-30","accession":"0001493152-26-013656","full_text":"https://origin.rootz.global/static/filing/0001493152-26-013656.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":41,"context":"l Market in the five (5) Business Days preceding the Business Day before the Intraday Purchase Notice and (ii) the Investors committed daily obligation set forth in Section 2(e) hereof. | -3- | | (t) Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, t","filed_date":"2025-09-11","accession":"0001493152-25-013094","full_text":"https://origin.rootz.global/static/filing/0001493152-25-013094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":33,"context":"ack, Inc. 2024 Equity Incentive Plan (the 2024 Plan) to increase the aggregate number of shares of Common Stock available for issuance under the 2024 Plan to 7,500,000 shares of Common Stock. | | Our named executive officers in this proxy statement, as determined under applicable SEC rules for smaller reporting companies like the Company is Paul V. Goode, our Chief Executive Officer. No cumulative voting rights are auth","filed_date":"2025-04-28","accession":"0001641172-25-006348","full_text":"https://origin.rootz.global/static/filing/0001641172-25-006348.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":51,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results, and financial condition. Until adequate reimbursement or insurance coverage is established, patients may have to bear the financial cost of our products. To mitiga","filed_date":"2025-03-31","accession":"0001641172-25-001861","full_text":"https://origin.rootz.global/static/filing/0001641172-25-001861.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":15,"context":"executive compensation for our last two completed fiscal years and an Outstanding Equity Awards at Fiscal Year End Table for our last completed fiscal year. These reporting obligations extend only to named executive officers. Individuals we refer to as our named executive officers include (i) all individuals serving as our Chief Executive Officer during the fiscal year ended December 31, 2024 and (ii) our two most highl","filed_date":"2025-03-31","accession":"0001641172-25-001861","full_text":"https://origin.rootz.global/static/filing/0001641172-25-001861.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":31,"context":"ck-Up Agreement, dated as of the date hereof, by and among the Placement Agent and the directors, officers, and 5% stockholders of the Company, substantially in the form of Exhibit A attached hereto. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Misconduct shall have the meaning ascribed to such ter","filed_date":"2024-11-18","accession":"0001493152-24-046564","full_text":"https://origin.rootz.global/static/filing/0001493152-24-046564.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":21,"context":"independent registered public accounting firm for the fiscal year ended December 31, 2023; | | |  5. |  To vote on the frequency of non-binding advisory votes regarding the executive compensation of named executive officers, every one (1), two (2) or three (3) years; and | | |  6. |  To transact such other business as may properly come before the Annual Meeting or any adjournment thereof. | | **The Board unanimously re","filed_date":"2024-04-01","accession":"0001493152-24-012324","full_text":"https://origin.rootz.global/static/filing/0001493152-24-012324.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":22,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results, and financial condition. Until adequate reimbursement or insurance coverage is established, patients may have to bear the financial cost of our products. | | 12 |","filed_date":"2024-03-28","accession":"0001493152-24-011765","full_text":"https://origin.rootz.global/static/filing/0001493152-24-011765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":11,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition. Until reimbursement or insurance coverage is established, patients will have to bear the financial cost of our products. Third-party covera","filed_date":"2023-03-31","accession":"0001493152-23-010356","full_text":"https://origin.rootz.global/static/filing/0001493152-23-010356.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":11,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition. Until reimbursement or insurance coverage is established, patients will have to bear the financial cost of GlucoTrack. Third-party coverage","filed_date":"2022-03-31","accession":"0001493152-22-008417","full_text":"https://origin.rootz.global/static/filing/0001493152-22-008417.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":11,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition. Until reimbursement or insurance coverage is established, patients will have to bear the financial cost of GlucoTrack. Third-party coverage","filed_date":"2021-04-13","accession":"0001493152-21-008654","full_text":"https://origin.rootz.global/static/filing/0001493152-21-008654.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":11,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition. Until reimbursement or insurance coverage is established, patients will have to bear the financial cost of GlucoTrack. Third-party coverage","filed_date":"2020-04-14","accession":"0001493152-20-006370","full_text":"https://origin.rootz.global/static/filing/0001493152-20-006370.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":12,"context":"d in the USA for achievements in innovative technology. The Board has determined that Dr. Fischell is suited to serve due to his extensive diabetes and medical device experience. **Shimon Rapps** was appointed as a Director of the Company on July 31, 2019. He is also Chair of Integritys Audit Committee. Mr. Rapps serves as Head of Investment Banking at Andrew Garrett, Inc., a full-service investment bank providing wealt","filed_date":"2020-04-14","accession":"0001493152-20-006370","full_text":"https://origin.rootz.global/static/filing/0001493152-20-006370.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"ls in connection with our application for FDA approval could also be substantially delayed or prevented by several factors, including: |  | | slower than expected rates of patient recruitment and enrollment; | | |  | | | | |  | | failure of patients to complete the clinical trial; | | |  | | | | |  | | unforeseen safety issues; | | |  | | | | |  | | lack of efficacy evidenced during clinical trials;","filed_date":"2019-04-15","accession":"0001493152-19-005323","full_text":"https://origin.rootz.global/static/filing/0001493152-19-005323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"the non-vested warrants that he was granted to him in the amount of approximately $1.1 Million, | | |  NOTE 19 |  MAJOR CUSTOMERS AND VENDORS | | |  |  For the year ended December 31, 2018, sales to one customer represented approximately 72% of net sales and purchases from two vendors represented approximately 84% of net purchases. | | | | F-41 | | | | | | INTEGRITY APPLICATIONS, INC. ** ** **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (c","filed_date":"2019-04-15","accession":"0001493152-19-005323","full_text":"https://origin.rootz.global/static/filing/0001493152-19-005323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":11,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition. Until reimbursement or insurance coverage is established, patients will have to bear the financial cost of GlucoTrack. Third-party coverage","filed_date":"2019-04-15","accession":"0001493152-19-005323","full_text":"https://origin.rootz.global/static/filing/0001493152-19-005323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":28,"context":"f of 2019. On October 2, 2018, John Graham notified the Company of his resignation as CEO and Chairman of the Company for personal reasons, to be effective as of October 31, 2018. David Podwalski was appointed as President and Chief Operating Officer of the Company by its Board, effective October 9, 2018, and was appointed as a Director effective as of October 31, 2018 to fill the vacancy created by Mr. Grahams resignation. Effe","filed_date":"2019-04-15","accession":"0001493152-19-005323","full_text":"https://origin.rootz.global/static/filing/0001493152-19-005323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"ive vote of a plurality of the shares of Voting Stock present in person or represented by proxy at the Annual Meeting. This means that the five nominees who receive the most affirmative votes will be elected to the Board of Directors. * * *Proposal 4 Ratification of our Auditors* * * If a quorum is present, this will require the affirmative vote of a majority of the shares of our Voting Stock present in person or in proxy at the","filed_date":"2018-11-23","accession":"0001493152-18-016686","full_text":"https://origin.rootz.global/static/filing/0001493152-18-016686.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"interim officers serving on the Board: |  |  |  an annual cash payment to each non-employee director and interim officer of the Company in the amount of $35,000, payable in four equal quarterly installments of $8,750 each on the last day of each calendar quarter commencing with the fourth quarter of 2017, subject to their continued service as of each such date; |  | |  |  |  an additional annual cas","filed_date":"2018-03-30","accession":"0001178913-18-001056","full_text":"https://origin.rootz.global/static/filing/0001178913-18-001056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"yment Agreement provides for the payment of certain social benefits and the use of a company car. |  | |  NOTE 19 |  |  MAJOR CUSTOMERS AND VENDORS |  | For the year ended December 31, 2017, sales to two customers represented approximately 94% of net sales and purchases from two vendors represented approximately 57% of net purchases. F - 43 INTEGRITY APPLICATIONS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) |  NOTE 20 |  |  SUB","filed_date":"2018-03-30","accession":"0001178913-18-001056","full_text":"https://origin.rootz.global/static/filing/0001178913-18-001056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ion. This means that Medicare dialysis rates in an environment of increasing expenses. These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us. There are ongoing discussions in the EU regarding amending the relevant regulatory framework. It is difficult to predict what effect any amendments to the existing EU legislation may have. Fur","filed_date":"2018-03-30","accession":"0001178913-18-001056","full_text":"https://origin.rootz.global/static/filing/0001178913-18-001056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":19,"context":"ths period following the date of grant. Effective April 7, 2017, the Company entered into an amendment to the employment agreement (the Graham Employment Amendment) with John Graham, whom the Company appointed as Chief Executive Officer on March 20, 2017, to modify the base compensation provision and the equity compensation provision under that certain Employment Agreement, dated March 20, 2017 (the Graham Effective Date), by and be","filed_date":"2018-03-30","accession":"0001178913-18-001056","full_text":"https://origin.rootz.global/static/filing/0001178913-18-001056.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":32,"context":"Date shall have the meaning ascribed to such term in Section 4.1(d). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Maximum Rate shall have the meaning ascribed to such t","filed_date":"2018-03-07","accession":"0001178913-18-000782","full_text":"https://origin.rootz.global/static/filing/0001178913-18-000782.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"in connection with our application for FDA approval could also be substantially delayed or prevented by several factors, including: |  |  |  slower than expected rates of patient recruitment and enrollment; |  | |  |  |  failure of patients to complete the clinical trial; |  | |  |  |  unforeseen safety issues; |  | |  |  |  lack of efficacy evidenced during clinical trials; |  | |  |  |  terminatio","filed_date":"2017-03-31","accession":"0001178913-17-001006","full_text":"https://origin.rootz.global/static/filing/0001178913-17-001006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ion. This means that Medicare dialysis rates in an environment of increasing expenses. These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us. There are ongoing discussions in the EU regarding amending the relevant regulatory framework. It is difficult to predict what effect any amendments to the existing EU legislation may have. Fur","filed_date":"2017-03-31","accession":"0001178913-17-001006","full_text":"https://origin.rootz.global/static/filing/0001178913-17-001006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":10,"context":"s, effective on that date. There are no arrangements or understandings between Mr. Darivoff, Ms. Strand and Mr. Seff and any other person pursuant to which Mr. Darivoff, Ms. Strand and Mr. Seff were selected as directors. Mr. Schwartz was appointed to the Board of Directors by Andrew Garrett, Inc. (AGI), the placement agent for the Companys ongoing private placement, pursuant to the terms of a letter agreement execu","filed_date":"2017-03-31","accession":"0001178913-17-001006","full_text":"https://origin.rootz.global/static/filing/0001178913-17-001006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":20,"context":"Date shall have the meaning ascribed to such term in Section4.1(d). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section3.1(b). Material Permits shall have the meaning ascribed to such term in Section3.1(m). Maximum Rate shall have the meaning ascribed to such ter","filed_date":"2016-04-14","accession":"0001178913-16-005077","full_text":"https://origin.rootz.global/static/filing/0001178913-16-005077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ates were flat in 2014 and will be flat 2015 in an environment of increasing expenses. These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us. 19 There are ongoing discussions in the EU regarding amending the relevant regulatory framework.It is difficult to predict what effect any amendments to the existing EU legislation may have.Fu","filed_date":"2016-03-30","accession":"0001178913-16-004924","full_text":"https://origin.rootz.global/static/filing/0001178913-16-004924.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ates were flat in 2014 and will be flat 2015 in an environment of increasing expenses. These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us. There are ongoing discussions in the EU regarding amending the relevant regulatory framework.It is difficult to predict what effect any amendments to the existing EU legislation may have.Furth","filed_date":"2015-03-31","accession":"0001178913-15-001111","full_text":"https://origin.rootz.global/static/filing/0001178913-15-001111.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":20,"context":"Date shall have the meaning ascribed to such term in Section4.1(d). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section3.1(b). Material Permits shall have the meaning ascribed to such term in Section3.1(m). Maximum Rate shall have the meaning ascribed to such ter","filed_date":"2014-09-05","accession":"0001178913-14-002852","full_text":"https://origin.rootz.global/static/filing/0001178913-14-002852.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"dialysis rates will be flat in 2014 and 2015 in an environment of increasing expenses. These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us. There are ongoing discussions in the EU regarding amending the relevant regulatory framework.It is difficult to predict what effect any amendments to the existing EU legislation may have.Furth","filed_date":"2014-03-28","accession":"0001178913-14-001124","full_text":"https://origin.rootz.global/static/filing/0001178913-14-001124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":26,"context":"nton Israel as the Companys independent registered public accounting firm for the 2013 fiscal year; |  | |  3. |  to approve, on an advisory (non-binding) basis, the compensation paid to the Companys named executive officers; |  | |  4. |  to vote, on an advisory (non-binding) basis, for your preference as to how frequently the Company should seek future advisory votes on the compensation of its named executive officers","filed_date":"2013-04-30","accession":"0001178913-13-001270","full_text":"https://origin.rootz.global/static/filing/0001178913-13-001270.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":12,"context":"that the reductions are expected to be seen in reimbursements beginning April 1, 2013.These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us. Reimbursement We anticipate that sales volumes and prices of the GlucoTrack DF-F and any other products we commercialize will depend in large part on the availability of reimbursement from thi","filed_date":"2013-04-01","accession":"0001178913-13-000956","full_text":"https://origin.rootz.global/static/filing/0001178913-13-000956.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":20,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning ascribed to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(m). Maximum Rate shall have the meaning ascribed to such t","filed_date":"2013-03-18","accession":"0001178913-13-000746","full_text":"https://origin.rootz.global/static/filing/0001178913-13-000746.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"stock could decline significantly and you could lose all or part of your investment. 26 A former stockholder of Integrity Israel who is entitled to receive shares in our company, subject to the fulfillment of certain requirements, has challenged our and Integrity Israels position that certain rights he had in Integrity Israel terminated upon the Reorganization. Integrity Israel is party to an invest","filed_date":"2012-03-14","accession":"0001178913-12-000703","full_text":"https://origin.rootz.global/static/filing/0001178913-12-000703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":10,"context":"edicare payments to dialysis facilities are expected to into effect on January 1, 2013.These measures and any future federal legislation relating to the debt ceiling or deficit reduction could have a material adverse effect on us. Reimbursement We anticipate that sales volumes and prices of the GlucoTrack DF-F and any other products we commercialize will depend in large part on the availability of reimbursement from thi","filed_date":"2012-03-14","accession":"0001178913-12-000703","full_text":"https://origin.rootz.global/static/filing/0001178913-12-000703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":23,"context":"e Merger Agreement or other specific dates solely for the benefit of certain of the parties to the Merger Agreement, which in certain cases are subject to specified exceptions and materiality, Lokahi Material Adverse Effect or Company Material Adverse Effect (each as defined in the Merger Agreement), knowledge and other qualifications contained in the Merger Agreement or in information provided pursuant to certain discl","filed_date":"2026-08-14","accession":"0001493152-26-038317","full_text":"https://origin.rootz.global/static/filing/0001493152-26-038317.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":96,"match_count":12,"context":"ive vote of a plurality of the shares of Voting Stock present in person or represented by proxy at the Annual Meeting. This means that the four nominees who receive the most affirmative votes will be elected to the Board of Directors. *Proposal 2 Ratification of our Auditors and Proposal 3 Say on Pay* If a quorum is present, this will require the affirmative vote of a majority of the shares of our Voting Stock present in person","filed_date":"2023-03-02","accession":"0001493152-23-006604","full_text":"https://origin.rootz.global/static/filing/0001493152-23-006604.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"mon stock could decline significantly and you could lose all or part of your investment. A former stockholder of Integrity Israel who is entitled to receive shares in our company, subject to the fulfillment of certain requirements, has challenged our and Integrity Israels position that certain rights he had in Integrity Israel terminated upon the Reorganization. Integrity Israel is party to a loan an","filed_date":"2014-03-28","accession":"0001178913-14-001124","full_text":"https://origin.rootz.global/static/filing/0001178913-14-001124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"in connection with our application for FDA approval could also be substantially delayed or prevented by several factors, including: |  |  |  slower than expected rates of patient recruitment and enrollment; | | |  |  |  | | |  |  |  failure of patients to complete the clinical trial; | | |  |  |  | | |  |  |  unforeseen safety issues; | | |  |  |  | | |  |  |  lack of efficacy evidenced during clini","filed_date":"2020-04-14","accession":"0001493152-20-006370","full_text":"https://origin.rootz.global/static/filing/0001493152-20-006370.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":88,"match_count":11,"context":"ing the date of grant. |  | |  |  3. |  Effective April 7, 2017, the Company entered into an amendment to the employment agreement (the Graham Employment Amendment) with John Graham, whom the Company appointed as Chief Executive Officer on March 20, 2017, to modify the base compensation provision and the equity compensation provision under that certain Employment Agreement, dated March 20, 2017 (the Graham Effective Date), by and be","filed_date":"2017-08-14","accession":"0001178913-17-002404","full_text":"https://origin.rootz.global/static/filing/0001178913-17-002404.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"mon stock could decline significantly and you could lose all or part of your investment. A former stockholder of Integrity Israel who is entitled to receive shares in our company, subject to the fulfillment of certain requirements, has challenged our and Integrity Israels position that certain rights he had in Integrity Israel terminated upon the Reorganization. Integrity Israel is party to a loan an","filed_date":"2013-04-01","accession":"0001178913-13-000956","full_text":"https://origin.rootz.global/static/filing/0001178913-13-000956.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":88,"match_count":11,"context":"gene Naidis.The directors hold office for one year terms and until their successors have been elected and qualified.The executive officers hold office for one year terms or until their successors are elected by the board of directors.The executive officers and directors of Integrity Israel are the same as our executive officers and directors, except that Elazar Sonnenschein, a designee of Dimri pursuant to the Investment Agreeme","filed_date":"2012-03-14","accession":"0001178913-12-000703","full_text":"https://origin.rootz.global/static/filing/0001178913-12-000703.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"in connection with our application for FDA approval could also be substantially delayed or prevented by several factors, including: |  |  |  slower than expected rates of patient recruitment and enrollment; | | |  |  |  | | |  |  |  failure of patients to complete the clinical trial; | | |  |  |  | | |  |  |  unforeseen safety issues; | | |  |  |  | | |  |  |  lack of efficacy evidenced during clini","filed_date":"2024-03-28","accession":"0001493152-24-011765","full_text":"https://origin.rootz.global/static/filing/0001493152-24-011765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"in connection with our application for FDA approval could also be substantially delayed or prevented by several factors, including: |  |  |  slower than expected rates of patient recruitment and enrollment; | | |  |  |  | | |  |  |  failure of patients to complete the clinical trial; | | |  |  |  | | |  |  |  unforeseen safety issues; | | |  |  |  | | |  |  |  lack of efficacy evidenced during clini","filed_date":"2023-03-31","accession":"0001493152-23-010356","full_text":"https://origin.rootz.global/static/filing/0001493152-23-010356.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":77,"match_count":9,"context":"of this Report. Directors of the Company hold office until the next annual meeting of our shareholders or until their successors have been elected and qualified. Executive officers of the Company are appointed by our board of directors and hold office until their death, resignation or removal from office. All directors serve for terms of one year each and are subject to re-election at Annual Meeting of Shareholders, unless they ea","filed_date":"2024-03-28","accession":"0001493152-24-011765","full_text":"https://origin.rootz.global/static/filing/0001493152-24-011765.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":72,"match_count":9,"context":"|  57 |  |  Chief Financial Officer | | |  Paul Goode |  |  54 |  |  President and Chief Operating Officer | | |  Shalom Shushan |  |  50 |  |  Chief Technology Officer | | **Paul V. Goode PhD** was named Chief Operating Officer of the Company on November 1, 2021, and previously served as a Director of the Company from December 17, 2020 to November 1, 2021. Mr. Goode most recently served as Vice President of Product Developm","filed_date":"2022-04-29","accession":"0001493152-22-011572","full_text":"https://origin.rootz.global/static/filing/0001493152-22-011572.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"cise price equal to the greater of (A) $5.20 per share or (B) the closing price of a share of Common Stock on the Effective Date, as reported by Bloomberg L.P., which shall vest in equal monthly installments over a three year period following the Effective Date. The bonus and equity incentives shall be subject to clawback rights if there is a misstatement of financials which changes any metrics upon","filed_date":"2022-03-31","accession":"0001493152-22-008417","full_text":"https://origin.rootz.global/static/filing/0001493152-22-008417.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"GCTK","company":"Glucotrack, Inc.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"d investment control over the shares held by Vayikra Capital LLC. (15) The address of Y.H. Dimri Holdings is 1 Jerusalem St. Netivot, 87710 Israel. Y.H. Dimri is entitled to these subject to the fulfillment of certain requirements. Yigal Dimri has voting and investment control over the shares held by Y.H. Dimri Holdings. (16) The address of Amos and Daughters Investments and Properties Ltd. is Shekel","filed_date":"2018-11-23","accession":"0001493152-18-016686","full_text":"https://origin.rootz.global/static/filing/0001493152-18-016686.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"76b7291dd723849e81d14e283dee7ee752dc6ed40a4dd8f3bfb738dbe3e70b2b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"bff28b67e02d9a2bc19481b04ce76a783dcaf6cf5817a9d91953c6ca8371bea1","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":25,"hourly_limit":500,"remaining":475,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}